LSE · POLB.L
Poolbeg Pharma PLC
£0.07-£0.00 (-2.26%)
Poolbeg Pharma PLC’s quoted price sits in the upper half of its reported 52-week range, 32.64% below the high.
Loading market information…
LSE · SAR.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 04:26 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Sareum Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 61.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sareum Holdings plc’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sareum Holdings plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform. Its development portfolio currently features programs targeting Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. Sareum has also forged strategic partnerships with the Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. Founded in 2003, the company is headquartered in Cambridge, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:06 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.07-£0.00 (-2.26%)
Poolbeg Pharma PLC’s quoted price sits in the upper half of its reported 52-week range, 32.64% below the high.
£0.83£0.00 (0.0%)
Arecor Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
£0.12£0.00 (0.0%)
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
£0.05-£0.00 (-2.68%)
Renalytix Plc’s quoted price sits in the upper half of its reported 52-week range, 35.12% below the high.
£0.19£0.00 (0.0%)
Inspiration Healthcare Group plc’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
£0.28£0.00 (0.0%)
Cambridge Cognition Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 37.78% below the high.
£0.02-£0.00 (-3.95%)
Genflow Biosciences Plc’s quoted price sits in the lower half of its reported 52-week range, 41.51% below the high.
£0.00-£0.00 (-1.67%)
Aptamer Group plc’s quoted price sits in the lower half of its reported 52-week range, 74.35% below the high.
